Dr. Ravi Salgia is a famous medical oncologist and researcher in Duarte, California. He has an extensive experience of more than two decades in the medical field. He has graduated from the Loyola University Chicago Stritch School of Medicine. He completed a residency in internal medicine at the John Hopkins University and a fellowship in medical oncology at the Dana-Farber Cancer Institute/ Harvard Medical School. Afterward, he became a faculty member of this institution. Dr. Salgia has been actively involved in the research field where his main concern is discovering new cancer treatments. His passion extended beyond the laboratory work as he also conducted multiple clinical trials. His intense research activity has been conducted for more than 10 years at the University of Chicago. Dr. Salgia’s studies were directed toward topics like the importance of the tyrosine kinases receptor in lung cancer, early diagnosis, and prognosis of thoracic cancer and tumor heterogeneity. All his endeavors aim to discover new and minimally invasive therapies which can improve patients’ life quality. Dr. Salgia’s research efforts have also amounted to numerous publications. He is the author of more than 200 articles and he brought a significant contribution to over 30 books that focus on thoracic conditions. His vast experience and proven knowledge turned him into one of the most in demand lecturers. He has been invited to participate in symposiums all over the world. Dr. Ravi Salgia is a board certified medical oncologist. He has received numerous distinction during his career: the America’s Top Doctor distinction in from 2008 to 2014, America's Top Doctors for Cancer, from 2007 to 2013, the Chicago Magazine: Top Doctors Recognition in 2012 and 2013. He currently practices medicine at the City of Hope Duarte - Comprehensive Cancer Center. Patients who want to benefit from his services can use the following insurances: Aetna, Aetna Choice POS II, MultiPlan, First Health PPO, Humana, United Healthcare.
Loyola University School of Medicine, Chicago, 1987
Johns Hopkins Hospital, Baltimore, 1987 to 1988
Johns Hopkins Hospital, Baltimore, 1988 to 1990
Dana-Farber Cancer Institute, Boston, 1990 to 1993
Harvard Medical School, Boston, 1990 to 1993
Brigham and Women\'s Hospital, 1990 to 1993
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V1, Won B2, Nagy R3, Banks K3, Lanman RB3, Talasaz A3, Salgia R4.See more >>
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R1, Riehm JJ1, Dhanasingh I1, Lennon FE1, Mirzapoiazova T1, Mambetsariev B1, Kindler HL1, Salgia R1.See more >>
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Won B1, Mambetsariev I2, Salgia R3.See more >>
American Association for Cancer Research
American Association for the Advancement of Science
American Society of Clinical Oncology
American Society of Hematology
International Association for the Study of Lung Cancer
Verified Patient ReviewsRate This Doctor
March 19, 2015
by Richard W
“I connected instantly with Dr. Salgia. He has impeccable credentials, a great bedside manner and really cares about his patients. I would never consider going to another doctor. ”